Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC

SIMPLE SUMMARY: MET is a receptor tyrosine kinase encoded by the MET proto-oncogene that has a significant role in cancer cell progression. Several drugs targeting MET are under development for the treatment of different cancers, including non-small-cell lung cancer (NSCLC). However, until now, rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Jørgensen, Jan Trøst, Mollerup, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105764/
https://www.ncbi.nlm.nih.gov/pubmed/35565287
http://dx.doi.org/10.3390/cancers14092150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105764/
https://www.ncbi.nlm.nih.gov/pubmed/35565287
http://dx.doi.org/10.3390/cancers14092150

Ejemplares similares